Related Experiment Video

Updated: Jul 25, 2026

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries
08:49

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries

Published on: January 22, 2019

Protein tyrosine phosphatase 1B inhibition: opportunities and challenges

Gang Liu1

  • 1Metabolic Disease Research, Abbott Laboratories, Abbott Park, IL 60064-6098, USA. gang.liu@abbott.com

Current Medicinal Chemistry
|July 23, 2003
PubMed

Insights

Protein tyrosine phosphatase 1B (PTP1B) is a key regulator of insulin and leptin signaling. Inhibiting PTP1B offers a promising therapeutic strategy for treating insulin resistance, type II diabetes, and obesity.

Area of Science:

  • Biochemistry
  • Pharmacology
  • Metabolic Diseases

Background:

  • Protein tyrosine phosphatase 1B (PTP1B) negatively regulates insulin and leptin signaling pathways.
  • PTP1B deficiency in mice improves insulin sensitivity, glycemic control, and obesity resistance.
  • PTP1B inhibition is a potential therapeutic target for metabolic disorders.

Purpose of the Study:

  • To review recent advancements in strategies for attenuating PTP1B activity.
  • To focus on small molecule PTP1B inhibitors and their therapeutic potential.
  • To discuss challenges in developing PTP1B inhibitors with favorable drug-like properties.

Main Methods:

  • Literature review of recent publications and patents.
  • Analysis of various approaches to inhibit PTP1B action.
  • Examination of small molecule inhibitor development for PTP1B.

Main Results:

  • PTP1B deficient mice exhibit enhanced insulin sensitivity and resistance to obesity.
  • Antisense oligonucleotides and small molecule inhibitors are explored for PTP1B targeted therapy.
  • Significant progress in PTP1B inhibitor research is indicated by recent publications and patents.

Conclusions:

  • Inhibiting PTP1B is a promising therapeutic avenue for insulin resistance, type II diabetes, and obesity.
  • Small molecule inhibitors represent a key focus in PTP1B-targeted drug development.
  • Further research is needed to overcome challenges in developing effective PTP1B inhibitors with drug-like properties.

More Related Videos

Assessing Cellular Target Engagement by SHP2 (PTPN11) Phosphatase Inhibitors08:45

Assessing Cellular Target Engagement by SHP2 (PTPN11) Phosphatase Inhibitors

Published on: July 17, 2020

Development and Application of Rapamycin-regulated Tyrosine Phosphatases06:56

Development and Application of Rapamycin-regulated Tyrosine Phosphatases

Published on: September 6, 2024

Related Concept Videos

Protein Kinases and Phosphatases02:54

Protein Kinases and Phosphatases

Proteins undergo chemical modifications that trigger changes in the charge, structure, and conformation of the proteins. Phosphorylation, acetylation, glycosylation, nitrosylation, ubiquitination, lipidation, methylation, and proteolysis are various protein modifications that regulate protein activity. Such modifications are usually enzyme-driven.
Protein kinases
Many proteins in the cell are regulated by phosphorylation, the addition of a phosphate group. A family of enzymes called kinases...
Protein Kinases and Phosphatases02:54

Protein Kinases and Phosphatases

Proteins undergo chemical modifications that trigger changes in the charge, structure, and conformation of the proteins. Phosphorylation, acetylation, glycosylation, nitrosylation, ubiquitination, lipidation, methylation, and proteolysis are various protein modifications that regulate protein activity. Such modifications are usually enzyme-driven.
Protein kinases
Many proteins in the cell are regulated by phosphorylation, the addition of a phosphate group. A family of enzymes called kinases...
Amplifying Signals via Enzymatic Cascade01:22

Amplifying Signals via Enzymatic Cascade

When a ligand binds to a cell-surface receptor, the receptor's intracellular domain changes shape, which may either activate its enzyme function or allow its binding to other molecules. The initial signal is amplified by most signal transduction pathways. This means that a single ligand molecule can activate multiple molecules of a downstream target. Proteins that relay a signal are most commonly phosphorylated at one or more sites, activating or inactivating the protein. Kinases catalyze the...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...